Ruilong Surgical has officially declared the successful closure of its Series D funding round, amassing a substantial $67 million. This round was predominantly led by Johnson & Johnson Innovation, a renowned name in the medical technology sector, with significant contributions also coming from Lilly Asia Ventures, INCE Capital, and Granite Asia. In conjunction with this financial milestone, Ruilong Surgical has forged a strategic partnership with Johnson & Johnson MedTech, marking a significant step forward in their collaborative endeavors. This alliance is poised to foster innovation and enhance the reach of their combined technological prowess in the medical field. Moreover, Ruilong Surgical's flagship product, the Haishan I® laparoscopic surgical robot system, has embarked on the registration and filing journey in both Europe and South America. This move underscores the company's commitment to expanding its global footprint and bringing cutting-edge surgical solutions to a wider audience.